New patients presenting to their GP with dyspepsia: does Helicobacter pylori eradication minimise the cost of managing these patients?
Fifty-seven patients newly presenting to their GP with dyspepsia agreed to take part in a pharmacist-led clinic which tested and treated for Helicobacter pylori. Of these patients, 63% (36/57) tested positive and received eradication therapy. For 78% (28/36), eradication was successful with the first course of treatment, 89% (25/28) remaining symptom-free over the six-month follow-up. Eradication was successful for a further 17% (6/36) after a second attempt; again, these patients remained free of symptoms over the follow-up period. Thus, of the initial patients, 54% (31/57) were successfully treated, with no further symptoms. Such results had significant consequences on the expected direct cost of management per patient from a GP viewpoint. Using decision analysis it was found that H. pylori eradication for patients presenting with dyspepsia for the first time could result in considerable cost savings per patient in the long term.
McIntyre
A M
AM
Pharmacoeconomic Research Centre, University of St Andrews, UK.
Macgregor
S
S
Malek
M
M
Dunbar
J A
JA
Hamley
J G
JG
Cromarty
J A
JA
D003663:Decision Trees; D004415:Dyspepsia / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D005194:Family Practice / Q000191:economics; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D012680:Sensitivity and Specificity